- Home
- VHUB vs PRPO Comparison
VHUB vs PRPO Comparison
Compare VHUB & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VHUB | PRPO |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.8M | 44.4M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | VHUB | PRPO |
|---|---|---|
| Price | $0.59 | $27.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 859.1K | 11.8K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $0.53 | $5.10 |
| 52 Week High | $15.34 | $29.53 |
Technical Indicators
Market Signals| Indicator | VHUB | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 19.10 | 53.52 |
| Support Level | $0.55 | $22.96 |
| Resistance Level | $0.69 | $28.76 |
| Average True Range (ATR) | 0.09 | 1.73 |
| MACD | 0.12 | 0.06 |
| Stochastic Oscillator | 11.35 | 64.33 |
Price Performance
Historical ComparisonAbout VHUB VenHub Global Inc. Common Stock
Venhub Global Inc is engaged in designing and building autonomous Smart Stores that operate 24/7 without on-site staff. Each store combines robotic automation, real-time inventory tracking, and mobile-based checkout to provide secure, convenient retail access, and is offered as an integrated retail solution to store operators.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.